
News|Articles|March 26, 2025
Q2 2025: 10 FDA Decisions to Watch
Author(s)HCPLive Editorial Staff
Fact checked by: Patrick Campbell
A Q2 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for dupilumab, pz-cel, ketamine, clesrovimab, and more!
Advertisement
Advertisement
The first quarter of 2025 set a high bar for drug approvals, with the US Food and Drug Administration (FDA) greenlighting several groundbreaking therapies. Suzetrigine (Journavx), a nonopioid pain reliever, broke a decades-long drought in FDA approvals for this critical area of unmet need. Meanwhile, semaglutide (Ozempic) expanded its reach, earning an indication for chronic kidney disease in type 2 diabetes, and esketamine (Spravato) made history as the first monotherapy for treatment-resistant depression.
Related to this article

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.
Advertisement
Advertisement

